Viridian is advancing a preclinical pipeline of potentially best-in-class therapeutic antibody programs, which includes VRDN-006 and VRDN-008, to be developed for rare and autoimmune diseases.
VRDN-006 is an anti-neonatal Fc receptor (FcRn)-targeting Fc fragment, and is designed to be a convenient, self-administered, subcutaneous product. Non-human primate studies have demonstrated specificity for blocking FcRn- immunoglobulin G (IgG) interactions while showing no decreases in albumin or increases in low-density lipoprotein (LDL) levels. In head-to-head non-human primate studies, VRDN-006 demonstrated comparable potency and IgG lowering to efgartigimod, the current standard of care in FcRn inhibition, as well as a similar safety profile.
VRDN-008 is a novel, first-in-class FcRn inhibitor and is also designed for convenient, subcutaneous self-administration. VRDN-008 aims to pair IgG suppression with extended half-life technology, potentially enabling deeper and more durable suppression than existing anti-FcRn therapies.